CMA
CORT icon

Cedar Mountain Advisors’s Corcept Therapeutics CORT Stock Holding History

Cedar Mountain Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39K Buy
+16
New +$966 ﹤0.01% 902
2026
Q1 		– Sell
-4
Closed -$139 – 1162
2025
Q4 		$139 Buy
+4
New +$314 ﹤0.01% 693

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cedar Mountain Advisors's CORT Position: Q2 2026 in Review

Cedar Mountain Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 16 shares worth $1.39K. The stake represents ﹤0.01% of the portfolio and ranks #902 among its holdings. This is a return to the name: Cedar Mountain Advisors previously reported a position in CORT as recently as Q4 2025.

Cedar Mountain Advisors first reported a position in CORT in Q4 2025 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Cedar Mountain Advisors held 16 shares of Corcept Therapeutics worth $1.39K as of Q2 2026.
  • Corcept Therapeutics was a new Cedar Mountain Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #902 holding.
  • Cedar Mountain Advisors first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.